Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Brazilian consensus on the diagnosis and treatment of extremities soft tissue sarcomas

2020; Wiley; Volume: 121; Issue: 5 Linguagem: Inglês

10.1002/jso.25847

1096-9098

Ranyell Matheus Spencer, Veridiana Pires de Camargo, Maria Letícia Gobo Silva, Fábio Fernando Elói Pinto, Felipe D’Almeida Costa, Wagner S. Cequeira, Rodrigo Ramella Munhoz, Celso Abdon Lopes de Mello, Rafael Schmerling, Waldec Jorge David Filho, Tharcísio Machado Coelho, Alexandre Ambrósio, Elton Trigo Teixeira Leite, Samir Abdallah Hanna, Suely Akiko Nakagawa, André Mathias Baptista, Rodrigo Nascimento Pinheiro, Jadivan Leite de Oliveira, Marcelo Sá de Araújo, Raphael L. C. Araújo, Gustavo Andreazza Laporte, Claudio Almeida Quadros, Alexandre Ferreira Oliveira, Ademar Lopes,

Cardiac tumors and thrombi

Abstract Introduction Soft tissue sarcomas (STSs) are rare tumors and constitute only 1% of all tumors in adults. Indeed, due to their rarity, most cases in Brazil are not treated according to primary international guidelines. Methods This consensus addresses the treatment of STSs in the extremities. It was made by workgroups from Brazilian Societies of Surgical Oncology, Orthopaedics, Clinical Oncology, Pathology, Radiology and Diagnostic Imaging, and Radiation Oncology. The workgroups based their arguments on the best level of evidence in the literature and recommendations were made according to diagnosis, staging, and treatment of STSs. A meeting was held with all the invited experts and the topics were presented individually with the definition of the degree of recommendation, based on the levels of evidence in the literature. Results Risk factors and epidemiology were described as well as the pathological aspects and imaging. All recommendations are described with the degree of recommendation and levels of evidence. Conclusion Recommendations based on the best literature regional aspects were made to guide professionals who treat STS. Separate consensus on specific treatments for retroperitoneal, visceral, trunk, head and neck sarcomas, and gastrointestinal stromal tumor, are not contemplated into this consensus.